2020文献快递：Nivolumab治疗肿瘤的副作用与临床疗效相关？

图1.A. irAE与OS的生存分析曲线；B. irAE与PFS的生存分析曲线

表1：免疫治疗疗效与irAEs的关系

参考文献：

1.Vitale MG, Pipitone S, Venturelli M, Baldessari C, Porta C, Iannuzzi F, Basso U, Scagliarini S, Zucali PA, Galli L et al: Correlation Between Immune-related Adverse Event (IRAE) Occurrence and Clinical Outcome in Patients With Metastatic Renal Cell Carcinoma (mRCC) Treated With Nivolumab: IRAENE Trial, an Italian Multi-institutional Retrospective Study. Clin Genitourin Cancer 2020.

2.Das S, Johnson DB: Immune-related adverse events and anti-tumor efficacy of immune checkpoint inhibitors. J Immunother Cancer 2019, 7(1):306.

3.Maher VE, Fernandes LL, Weinstock C, Tang S, Agarwal S, Brave M, Ning YM, Singh H, Suzman D, Xu J et al: Analysis of the Association Between Adverse Events and Outcome in Patients Receiving a Programmed Death Protein 1 or Programmed Death Ligand 1 Antibody. J Clin Oncol 2019, 37(30):2730-2737.

4.Berner F, Bomze D, Diem S, Ali OH, Fassler M, Ring S, Niederer R, Ackermann CJ, Baumgaertner P, Pikor N et al: Association of Checkpoint Inhibitor-Induced Toxic Effects With Shared Cancer and Tissue Antigens in Non-Small Cell Lung Cancer. JAMA Oncol 2019, 5(7):1043-1047.

5.Johnson DB, McDonnell WJ, Gonzalez-Ericsson PI, Al-Rohil RN, Mobley BC, Salem JE, Wang DY, Sanchez V, Wang Y, Chastain CA et al: A case report of clonal EBV-like memory CD4(+) T cell activation in fatal checkpoint inhibitor-induced encephalitis. Nat Med 2019, 25(8):1243-1250.

长按下方二维码关注

刘宝瑞肿瘤医疗网络平台

南京大学鼓楼医院肿瘤中心 主任医师 教授

专注于肿瘤个体化及靶向药物治疗

新抗原疫苗及靶向免疫治疗

精准放疗及中西医结合治疗

原文始发于微信公众号（刘宝瑞肿瘤医疗网络平台）：2020文献快递：Nivolumab治疗肿瘤的副作用与临床疗效相关？